Table 2 The most frequent moderately-late side effects recorded
From: IMRT sparing of normal tissues in locoregional treatment of breast cancer
Moderately-late side effects | ||||||||
|---|---|---|---|---|---|---|---|---|
Adverse events | Grade | Baseline | 3Â months | 6Â months | 12Â months | 18Â months | 24Â months | 30Â months |
30 pts | 30 pts | 30 pts | 29 pts | 28 pts | 27 pts | 26 pts | ||
Erythema pigmentation | Grade 0 | Â | 6 | 14 | 18 | 22 | 23 | 22 |
Grade1 | Â | 23 | 16 | 11 | 6 | 4 | 4 | |
Grade2 | Â | 1 | 0 | 0 | 0 | 0 | 0 | |
Induration fibrosis | Grade 0 | Â | 23 | 23 | 22 | 24 | 23 | 22 |
Grade 1 | Â | 6 | 6 | 7 | 4 | 4 | 4 | |
Grade 2 | Â | 1 | 1 | 0 | 0 | 0 | 0 | |
Telangiectasia | Grade 0 | Â | 30 | 30 | 29 | 26 | 23 | 21 |
| Â | Grade 1 | Â | 0 | 0 | 0 | 2 | 4 | 4 |
| Â | Grade 2 | Â | 0 | 0 | 0 | 0 | 0 | 1 |
Breast/chest wall pain | Grade 0 | 23 | 13 | 16 | 17 | 18 | 20 | 20 |
Grade 1 | 6 | 16 | 13 | 12 | 9 | 6 | 6 | |
Grade 2 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | |
Grade 3 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
Cough/dyspnea | Grade 0 | 27 | 28 | 28 | 26 | 25 | 26 | 26 |
Grade 1 | 3 | 2 | 2 | 3 | 2 | 1 | 0 | |
MSK upper limb treated/neurosensitive symptoms | Grade 0 | 18 | 24 | 25 | 25 | 25 | 25 | 26 |
Grade 1 | 10 | 5 | 4 | 4 | 3 | 3 | 1 | |
Grade 2 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | |